FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171968270> ?p ?o ?g. }

• W3171968270 endingPage "TPS6093" @default.
• W3171968270 startingPage "TPS6093" @default.
• W3171968270 abstract "TPS6093 Background: Since patients with early-stage oral cavity cancer (OCC; T1-2N0M0; AJCC 8 th ed) have a 20-30% rate of occult nodal metastases despite clinical and radiographic assessment, standard of care treatment includes elective neck dissection (END). Many patients have comprehensive surgical management of the regional cervical nodal basin even though the majority of those necks (70-80%) will not contain disease. Assessment of draining first echelon lymph nodes by sentinel lymph node (SLN) biopsy (Bx), a less invasive surgical procedure, may provide an alternative to END, while potentially reducing morbidity and cost. A decisive clinical trial comparing SLN Bx versus END can focus the HNC clinical and research community and resources on establishing the standard of care for management of the neck in early-stage OCC. Methods: In order to address the efficacy of SLN Bx in this population, we recently activated an international multi-institutional phase II/III prospective trial randomizing patients to two surgical arms: SLN Bx and END. PET/CT is an integral imaging biomarker in this trial. A node-negative PET/CT study with central read is required before randomization. Patients with a positive PET/CT central result will remain in a registry to compare imaging findings with final neck pathology. Given the current evidence available regarding morbidity for SLN Bx versus END, the phase II will determine if patient-reported neck and shoulder function and related QOL at 6 months after surgery using the Neck Dissection Impairment Index (NDII) shows a signal of superiority of SLN Bx compared to END. A total of 228 randomized patients with negative PET/CT for potential evaluation of shoulder-related morbidity with difference in 6-month NDII scores (minimum important difference ³7.5; one-sided a = 0.10; 90% power) will serve as the “Go/No-Go” decision to move forward into phase III. The phase III portion is a non-inferiority (NI) trial with disease-free survival (DFS) as the primary endpoint (NI margin hazard ratio 1.34 based on a 5% absolute difference in 2-year DFS; one-sided alpha 0.05; 80% power, and an interim look for efficacy at 67% of the events based on an O’Brien-Fleming boundary). The NDII at 6 months after surgery is a hierarchical co-primary endpoint for the phase III. Target accrual of phase III is 618 PET/CT negative patients, including those randomized in phase II (297 DFS events required for the final analysis). In addition to radiotherapy and imaging credentialing, quality assurance will include central pathology review of all negative SLN Bx cases and surgeon credentialing through an education course and SLN Bx and END case review by the surgical co-chairs. A surgical quality assurance working group will review all trial SLN Bx and END outcomes. As of 02/15/21, 7 patients have been screened and 6 of the planned 228 randomized patients in phase II have been enrolled. Clinical trial information: NCT04333537." @default.
• W3171968270 created "2021-06-22" @default.
• W3171968270 creator A5001313680 @default.
• W3171968270 creator A5005217161 @default.
• W3171968270 creator A5008367011 @default.
• W3171968270 creator A5010191084 @default.
• W3171968270 creator A5013860869 @default.
• W3171968270 creator A5027993575 @default.
• W3171968270 creator A5032709498 @default.
• W3171968270 creator A5043045096 @default.
• W3171968270 creator A5047821139 @default.
• W3171968270 creator A5051293558 @default.
• W3171968270 creator A5062486053 @default.
• W3171968270 creator A5066224894 @default.
• W3171968270 creator A5069799062 @default.
• W3171968270 creator A5074092583 @default.
• W3171968270 creator A5081282369 @default.
• W3171968270 creator A5081622824 @default.
• W3171968270 creator A5083147441 @default.
• W3171968270 creator A5085120914 @default.
• W3171968270 date "2021-05-20" @default.
• W3171968270 modified "2023-10-16" @default.
• W3171968270 title "NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer." @default.
• W3171968270 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.tps6093" @default.
• W3171968270 hasPublicationYear "2021" @default.
• W3171968270 type Work @default.
• W3171968270 sameAs 3171968270 @default.
• W3171968270 citedByCount "2" @default.
• W3171968270 countsByYear W31719682702023 @default.
• W3171968270 crossrefType "journal-article" @default.
• W3171968270 hasAuthorship W3171968270A5001313680 @default.
• W3171968270 hasAuthorship W3171968270A5005217161 @default.
• W3171968270 hasAuthorship W3171968270A5008367011 @default.
• W3171968270 hasAuthorship W3171968270A5010191084 @default.
• W3171968270 hasAuthorship W3171968270A5013860869 @default.
• W3171968270 hasAuthorship W3171968270A5027993575 @default.
• W3171968270 hasAuthorship W3171968270A5032709498 @default.
• W3171968270 hasAuthorship W3171968270A5043045096 @default.
• W3171968270 hasAuthorship W3171968270A5047821139 @default.
• W3171968270 hasAuthorship W3171968270A5051293558 @default.
• W3171968270 hasAuthorship W3171968270A5062486053 @default.
• W3171968270 hasAuthorship W3171968270A5066224894 @default.
• W3171968270 hasAuthorship W3171968270A5069799062 @default.
• W3171968270 hasAuthorship W3171968270A5074092583 @default.
• W3171968270 hasAuthorship W3171968270A5081282369 @default.
• W3171968270 hasAuthorship W3171968270A5081622824 @default.
• W3171968270 hasAuthorship W3171968270A5083147441 @default.
• W3171968270 hasAuthorship W3171968270A5085120914 @default.
• W3171968270 hasConcept C121608353 @default.
• W3171968270 hasConcept C126322002 @default.
• W3171968270 hasConcept C126838900 @default.
• W3171968270 hasConcept C141071460 @default.
• W3171968270 hasConcept C146357865 @default.
• W3171968270 hasConcept C151730666 @default.
• W3171968270 hasConcept C168563851 @default.
• W3171968270 hasConcept C179671157 @default.
• W3171968270 hasConcept C2775862295 @default.
• W3171968270 hasConcept C2775934546 @default.
• W3171968270 hasConcept C2778474501 @default.
• W3171968270 hasConcept C2780212769 @default.
• W3171968270 hasConcept C2780849966 @default.
• W3171968270 hasConcept C2908647359 @default.
• W3171968270 hasConcept C530470458 @default.
• W3171968270 hasConcept C71924100 @default.
• W3171968270 hasConcept C86803240 @default.
• W3171968270 hasConcept C99454951 @default.
• W3171968270 hasConceptScore W3171968270C121608353 @default.
• W3171968270 hasConceptScore W3171968270C126322002 @default.
• W3171968270 hasConceptScore W3171968270C126838900 @default.
• W3171968270 hasConceptScore W3171968270C141071460 @default.
• W3171968270 hasConceptScore W3171968270C146357865 @default.
• W3171968270 hasConceptScore W3171968270C151730666 @default.
• W3171968270 hasConceptScore W3171968270C168563851 @default.
• W3171968270 hasConceptScore W3171968270C179671157 @default.
• W3171968270 hasConceptScore W3171968270C2775862295 @default.
• W3171968270 hasConceptScore W3171968270C2775934546 @default.
• W3171968270 hasConceptScore W3171968270C2778474501 @default.
• W3171968270 hasConceptScore W3171968270C2780212769 @default.
• W3171968270 hasConceptScore W3171968270C2780849966 @default.
• W3171968270 hasConceptScore W3171968270C2908647359 @default.
• W3171968270 hasConceptScore W3171968270C530470458 @default.
• W3171968270 hasConceptScore W3171968270C71924100 @default.
• W3171968270 hasConceptScore W3171968270C86803240 @default.
• W3171968270 hasConceptScore W3171968270C99454951 @default.
• W3171968270 hasFunder F4320332161 @default.
• W3171968270 hasIssue "15_suppl" @default.
• W3171968270 hasLocation W31719682701 @default.
• W3171968270 hasOpenAccess W3171968270 @default.
• W3171968270 hasPrimaryLocation W31719682701 @default.
• W3171968270 hasRelatedWork W1908828519 @default.
• W3171968270 hasRelatedWork W2074935102 @default.
• W3171968270 hasRelatedWork W2090463034 @default.
• W3171968270 hasRelatedWork W2135056394 @default.
• W3171968270 hasRelatedWork W2406874692 @default.
• W3171968270 hasRelatedWork W2418268142 @default.
• W3171968270 hasRelatedWork W2429741279 @default.
• W3171968270 hasRelatedWork W2442339248 @default.
• W3171968270 hasRelatedWork W4312712614 @default.

• next